Royalty Report: Drug Discovery, Therapeutic, Software – Collection: 250927


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drug Discovery
  • Therapeutic
  • Software
  • Medical Info
  • Drugs
  • Assay
  • Disease
  • DNA
  • Genome

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 250927

License Grant
The Company entered into an agreement with Licensor to offer therapeutic antibody design and optimization services, as well as an exclusive library targeting G-protein coupled receptors to our customers. The Company also agreed on a profit-sharing and license arrangement for an Antibody Optimization Software and GPCR-Targeting Antibody Library.
License Property
The custom software, to be developed by Licensor exclusively for Licensee, will enable pharmaceutical and biotechnology companies to easily use Twist Bioscience's high-throughput long oligo synthesis technology to revolutionize how they design, engineer and optimize their antibody leads to identify high quality, fully-human antibody therapeutics while simultaneously receiving synthetic DNA to complete early drug discovery. Additionally, the proprietary GPCR targeting antibody library will be available for customers to screen, in order to identify novel therapeutics against this valuable class of targets.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 222558

License Grant
For the Compounds and Products, Licensor grants an exclusive license under the Licensor Technology and Licensors interest in the Collaboration Technology, exclusive even as to Licensor and its Affiliates, to make, have made, use, sell, offer to sell, import and export Agreement Products in the Territory. It is understood that such licenses shall include the right to conduct drug research and development, and the exclusive right to discover, develop, make, have made and use Agreement Compounds, during the term of this Agreement.

For the Collaboration Target-Specific Technology, Licensor grants an exclusive license, exclusive even as to  Licensor and its Affiliates, under all of Licensors interest in the Collaboration Target-Specific Technology for any and all purposes in the Territory, including the right to grant sublicenses.

For the Collaboration Platform Technology, upon conclusion of the Collaboration Term, the Parties each  grant, to the other a co-exclusive license under their respective interests in the Collaboration Platform Technology in the Territory, as follows:  the Parties may each use such Collaboration Platform Technology for any and all internal uses, including without limitation, in collaboration with Third Parties for drug discovery.

For the Columbia Sublicense, Licensor grants a non-exclusive sublicense, without the right to sublicense, under the Columbia License, to make, have made, use, offer to sell, sell, import and export Agreement Products in the Territory, including, without limitation, the right to decode Library Compounds.

License Property
Licensor has developed proprietary technologies relating to the design and preparation of encoded compound libraries based upon combinatorial chemistry.  'Licensor Technology' shall mean Existing Licensor Patent Rights, Existing Licensor Know-How, and Licensor Improvements (with some exceptions).

Product means any Agreement Product or Licensees Product.

Agreement Product shall mean any product containing an Agreement Compound, including, without limitation, products for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings or animals.

Licensees Product shall mean any product for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings containing a Licensee Compound, provided such Licensee Product is not a Combination Product containing both a Licensee Compound and an Agreement Compound.

Active Compound shall mean a Library Compound that demonstrates activity against a specific Target, which Library Compound was found to have such activity at a concentration set forth in the applicable Collaboration Research Plan during screening of one or more Libraries by Licensor in the conduct of the Collaboration or was found to have such activity during screening by or on behalf of Licensee.

Licensor's combinatorial chemistry technology as an important component in our ongoing efforts to accelerate the drug discovery process and to identify lead compounds for development as new therapeutic entities.'

Field of Use
This agreement field relates to assays, compound screening methods and biological research tools used to design, prepare and screen compound libraries against Licensees biological targets.

IPSCIO Record ID: 203310

License Grant
With this collaboration agreement, Licensor will develop and deliver to Licensee, a non-profit organization, The OmniBank II Library, install and support the Bioinformatics Software, and provide training to Licensees staff in the use of the OmniBank II Library and the production, genotyping and phenotyping of knockout mice.

Licensor will generate and deliver to Licensee two complete copies of a library consisting of three hundred fifty thousand (350,000) mouse embryonic stem cell clones with Selected Mutations, each identified by DNA sequence of its genomic integration site, the OmniBank II Library. Subject to the terms of this Agreement, Licensor will use Diligent Efforts to generate and deliver the OmniBank II Library in accordance with the schedule set forth in the Development Plan.

Licensor grants to Licensee the non-transferable, non-exclusive right under Licensors rights in the Cre-Lox Patents to use, breed and cross-breed Mutant Mice and Progeny that contain one or more lox sites in their genome (Lox Mice), at the internal research facilities of Licensee, solely for research purposes.

Licensor grants to Licensee a worldwide, non-exclusive right and license to use the Bioinformatics Software, under the copyrights and know-how Controlled by Licensor with respect thereto. Licensee shall have the right under the foregoing license to custom configure the Bioinformatics Software for its internal use.

License Property
Licensor has technology for and expertise in the generation of mouse embryonic stem cell clones containing gene trap mutations that can be used in the production of knockout mice.

The Bioinformatics Software means the software for the management and analysis of data relating to the OmniBank II Library and the production, genotyping and phenotypic analysis of knockout mice.

The library, constructed using Licensor's proprietary mouse gene knockout technology, will enable a researcher to develop a mouse that has a specific gene removed or “knocked-out.” The function of that gene can then be studied by comparing the knockout mouse to a normal mouse. Approximately 99 percent of human genes have a mouse counterpart, and research using this technology may lead to the development of drugs for a wide variety of human and animal diseases, including diabetes and obesity, infectious disease, cancer and heart disease. Institute researchers will have certain rights to utilize Lexicon’s patented gene targeting technologies. In addition, Licensor will equip the Institute with the bioinformatics software required for the management and analysis of data relating to the library.

Field of Use
This agreement is for the stem cell cloning industry and the identification of target genes and DNA.

IPSCIO Record ID: 203543

License Grant
Licensor grants to the Licensee of China and its Affiliate, with respect only to the Licensees Activated Receptor that is the subject of the Screening Assay Notice:
(a) an exclusive right and license under the Technology, exclusive even as to Licensor,  to use, have used, sell, have sold, import, have imported, further develop, improve and otherwise exploit in any manner the Licensees Activated Receptor, for the purpose of identification of CART Identified Compound(s) in the Territory, and
(b) an exclusive right and license under the Technology, exclusive even as to Licensor, to develop, manufacture, have manufactured, promote, market, sell, distribute and, license CART Identified Compound(s) and/or Drug Product(s) in the Territory.
License Property
CART identified compounds means a compound, and/or a Derivative of a CART Identified Compound, that has been identified as a modulator of a Licensee Activated Receptor by Licensee during the term of this Agreement or by Licensor Screening.

Drug product means a therapeutic product comprising a CART Identified Compound.

Licensees Activated Receptor means a Licensee Selected GPCR to which the Licensor Activation Technology has been applied.

G Protein Coupled Receptor and GPCR means an Endogenous cell-surface receptor defined by having three (3) intracellular loops, three (3) extracellular loops, an amino terminus and a carboxy terminus.

Licensor is an emerging biopharmaceutical company focused principally on discovering drugs that act on an important class of drug targets called G protein-coupled receptors, or GPCRs. Licensor has developed a technology called Constitutively Activated Receptor Technology, or CART, that can be applied to GPCRs and other classes of receptors to identify drug leads. Licensor believesthat CART is a more efficient drug discovery technique than traditional drug discovery techniques.

Field of Use
Licensee is a biopharmaceutical organization focused on the discovery and development of innovative therapeutics.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.